Advertisement
Canada markets close in 1 hour 42 minutes

  • S&P/TSX

    21,977.74
    +92.36 (+0.42%)
     

  • S&P 500

    5,106.41
    +57.99 (+1.15%)
     

  • DOW

    38,288.44
    +202.64 (+0.53%)
     

  • CAD/USD

    0.7318
    -0.0005 (-0.07%)
     

  • CRUDE OIL

    83.91
    +0.34 (+0.41%)
     

  • Bitcoin CAD

    87,427.98
    -1,057.29 (-1.19%)
     

  • CMC Crypto 200

    1,331.87
    -64.66 (-4.63%)
     

  • GOLD FUTURES

    2,350.40
    +7.90 (+0.34%)
     

  • RUSSELL 2000

    2,003.78
    +22.66 (+1.14%)
     

  • 10-Yr Bond

    4.6730
    -0.0330 (-0.70%)
     

  • NASDAQ

    15,932.76
    +321.00 (+2.06%)
     

  • VOLATILITY

    15.10
    -0.27 (-1.76%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6838
    +0.0017 (+0.25%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Latest stubborn U.S. inflation reading will bring about more 'wait and see' from the Fed

Cardiol Therapeutics says first patient enrolled in Phase 2 study of CardiolRx for Pericarditis

News Direct
·1 min read

Vancouver, BC --News Direct-- Cardiol Therapeutics

Cardiol Therapeutics CEO David Elsley shared news the company has hit a major milestone in that the first patient has been enrolled in a Phase II open-label pilot study of CardiolRx in patients with recurrent pericarditis. Elsley told Proactive the study is designed to evaluate improvement in objective measures of disease and assess the feasibility of weaning concomitant background therapy including corticosteroids, while taking CardiolRx. The study is expected to enroll 25 patents.

Proactive Canada Financial News

Contact Details

Proactive Canada

Proactive Canada

ADVERTISEMENT

+1 604-688-8158

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/cardiol-therapeutics-says-first-patient-enrolled-in-phase-2-study-of-cardiolrx-for-pericarditis-132503438